01878nas a2200169   4500008004100000020001400041245012600055210006900181260030700250300001600557490000700573520102400580100001801604700002101622700001601643856004901659       2009                        eng d  a1058-483800aCryptococcosis in Solid-Organ, Hematopoietic Stem Cell, and Tissue Transplant Recipients: Evidence-Based Evolving Trends.0 aCryptococcosis in SolidOrgan Hematopoietic Stem Cell and Tissue   a(C) Copyright Oxford University Press 2009.b(1)VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania(2)University of Pittsburgh, Pittsburgh, Pennsylvania(3)Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwanc2009  a1566 - 15760 v483 a: The impact of current transplantation practices on the characteristics of cryptococcosis in solid-organ transplant recipients is not well defined. The incidence of cryptococcal disease among solid-organ transplant recipients has remained unchanged; however, patients are less likely to present with central nervous system or disseminated disease and are more likely to have cryptococcosis limited to the lungs. Additionally, lipid formulations of amphotericin B are now used more frequently, whereas their use in combination with flucytosine has decreased. The overall mortality of cryptococcosis has significantly improved in the current era. Renal failure remains associated with poor outcome, whereas use of lipid formulations of amphotericin B is associated with a higher survival rate. Despite rare infectious complication, certain peculiar attributes of cryptococcal disease in hematopoietic stem cell recipients and tissue transplant recipients warrant recognition., (C) Copyright Oxford University Press 2009.1 aSun, Hsin-Yun1 aWagener, Marilyn1 aSingh, Nina  uhttps://www.notifylibrary.org/reference/4331